drug discovery

AACT, Inc. is a research-and-development-stage biopharmaceutical company focused on oncology, developing small-molecule, patent-protected drugs that exploit biological differences between tumor and normal cells. Its technology derives from research at the Icahn School of Medicine at Mount Sinai and the Fels Institute for Cancer Research and Molecular Biology of Temple University School of Medicine. Lead candidates include AA150030 and AA108600. AACT also runs an antiviral program developing broad-spectrum host-directed antivirals.

kinase inhibitor developmentmedicinal chemistrynebulized pulmonary drug deliverypreclinical testing

Aayam is a therapeutics company focused on delivering affordable and accessible therapeutics to patients. It uses a unique drug development technology platform called LADR 4 and aims to create a global collaborative network for drug discovery and development.

drug development

Abilita Therapeutics is a drug discovery company whose capabilities are founded on its EMP™ technology, based on the principles of directed evolution. Enabled Membrane Proteins (EMPs™) are stability and expression enhanced variants that enable discovery and optimization of drug candidates, aiming to unlock the therapeutic potential of membrane protein targets. The company is located in San Diego, California.

directed evolutiondrug candidate optimization

Accuitis is a late pre-clinical stage pharmaceutical company with multiple compounds in development that were discovered at Emory University. Its lead compound AN-018 is a small molecule validated in preclinical research to restore mitochondrial SIRT3 expression and healthy cellular function in neurodegenerative, age-related, and metabolic diseases such as Alzheimer's, Parkinson's disease, and methamphetamine addiction. The privately-funded company focuses on creating a preventive therapeutic for neurodegenerative disease progression.

preclinical research and development

AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. It uses its proprietary disease-modeling platform iNeuroRx® to generate individual patient models that recapitulate neurodegenerative disease processes, aiming to discover novel, effective and broadly-acting treatments. The company has a growing pipeline of antisense oligonucleotide (ASO) treatments, including lead clinical candidate AS-241.

AIantisense oligonucleotide (ASO) therapeuticsBioinformaticsbiomarker developmentdisease modelingtranslational science

ADRx, Inc. is a drug discovery company with an innovative platform that transforms atomic structures into small molecule therapies to treat Alzheimer's, ALS, Parkinson's Disease, and more. It describes itself as the first company to successfully apply structure-based design to disrupt protein aggregation diseases, with the ability to identify, design and develop therapeutics to patient-derived pathological protein structures.

small molecule modulator discoverystructure-based designtherapeutic design and development

AfaSci Inc. is a San Francisco Bay Area biopharmaceutical company developing life-changing pain and epilepsy medications. It provides contract services to the R&D community, leveraging drug discovery expertise in pain, epilepsy, stroke and Alzheimer's disease, along with proprietary instruments for automated rodent behavioral monitoring.

behavioral assaysEEG/EMG in vivoelectrophysiologyhistopathologyimmunohistochemistryIn vivo PK/PDMEA-64 recordingsneurobehavior toxicity testingpatch clamppharmacology

AgeneBio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapeutics for patients at risk for neurological and psychiatric conditions, with the goal of preserving and restoring brain function. Its lead late-stage clinical program, AGB101, is being evaluated for amnestic mild cognitive impairment due to Alzheimer's disease (MCI due to AD) in the HOPE4MCI Phase 2b trial. It also has a discovery program developing GABA(A) α5 positive allosteric modulators.

Chemistry Manufacturing & Controls (CM&C) developmentclinical developmentdrug development

Akanocure is a drug development company with a focus on orphan and unmet needs in oncology. Applying expertise throughout the drug discovery and development process, it creates novel small molecules intended to positively impact the lives of cancer patients. Its mission is to find therapeutic approaches that block metastatic processes, and it integrates chemical methodology development with classic drug discovery expertise through collaboration with industry leaders, academia, and government.

chemical methodology developmentchemistry platformdrug developmentsmall molecule development

AKAVA Therapeutics is a biotechnology company developing first-in-class small molecule inhibition therapeutics for neurodegenerative diseases and cancers. Its lead compound AKV9 targets protein aggregation and has been investigated in ALS, hereditary spastic paraplegia, frontotemporal dementia, and Alzheimer's disease. The company was established in 2019 as a commercialization arm for compounds from the Silverman Laboratory at Northwestern University.

drug developmentsmall-molecule therapeutics

ALIGOS Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH). The company targets liver and viral diseases with best-in-class therapies, leveraging medicinal chemistry and biology teams to build a differentiated pipeline.

biology researchdrug developmentmedicinal chemistry

Aluda Pharmaceuticals is a drug discovery company focused on novel targets for complex diseases, particularly immune and fibrotic diseases. It designs new drug molecules using tools including CRISPR, proteomic array analysis, genetics, molecular medicine, cell biology, big data, and chemical design, and pioneered proprietary concepts in phenotypic screening. Its lead program is a first-in-class anti-vimentin program for fibrosis.

big datacell biologychemical designCRISPRgeneticsmolecular medicinephenotypic screeningproteomic array analysis

Transform Therapies, Reimagine Lives Our Mission Transform treatment for immune-mediated diseases, empower people to reimagine their lives. About Alumis Our Programs We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases. PIPELINE Our Approach Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development. science Our Culture We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward. careers News October 9, 2026 Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures September 4, 2026 Alumis to Participate in Upcoming.

clinical trialsdata analytics platformtherapeutic development

Amgen is a biotechnology company that discovers, develops, manufactures and delivers innovative medicines for serious illnesses. Founded in 1980 in Thousand Oaks, California, it pioneered the use of living cells to make biologic medicines and focuses on general medicine, rare disease, inflammation and oncology, with a presence in approximately 100 countries.

AI and data science in drug discoverybiotechnologyclinical trialsmanufacturing of biologic medicinesresearch and development

Amygdala Neurosciences is a biopharmaceutical company headquartered in San Francisco, CA, founded in 2015. Its mission is to address the unmet need associated with alcohol use disorder (AUD) and other substance use disorders (SUD) by discovering, developing, and commercializing safe and effective pharmacotherapies to treat addiction. The company was formed based on technology targeting the enzyme aldehyde dehydrogenase type 2 (ALDH2), acquired from Gilead Sciences.

pharmacotherapy developmentpreclinical development

Annovis Bio is a Phase 3 clinical-stage biotechnology company developing transformative therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its goal is to develop effective treatments by restoring nerve cell function and improving cognitive and motor abilities in patients. The company was founded in 2008 by Dr. Maria Maccecchini and is listed on the NYSE under ANVS.

biostatisticsclinical developmentclinical trial operationsGMP operationspilot plant productionprocess chemistry R&Dregulatory strategy and FDA submissions

Antidote Therapeutics is a science-driven biopharmaceutical company developing first-in-class nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Its proprietary treatments target rare vascular diseases and addiction, including a fully human anti-nicotine monoclonal antibody. Initial indications include orphan vascular diseases in smokers such as Buerger's Disease and Critical Limb Ischemia.

clinical research collaborationdrug developmentimmunotherapeutic approachesmonoclonal antibody development

Anviron is a University Co-founded team of oncologists and biochemists specialized in glycome oncology, founded in 2020 and based in Newport Beach, California. The company develops small molecule inhibitors of proteins responsible for proliferation signaling and metastasis, including drug candidates ANV221 and ANV322 for pancreatic cancer and advanced, drug-resistant HER2-positive breast cancer.

glycome oncology researchmedicinal chemistryoncology therapeutics development

Aperture Therapeutics is building a drug discovery platform that embraces the genetic diversity of patients and leverages mechanistic understanding of protective gene variants in the human population. Its platform identifies naturally occurring gene variants that protect against neurodegeneration, using machine learning to mine large-scale genomic and clinical datasets to prioritize gene variants with the strongest protective effects and rapidly design oligonucleotide therapeutics mimicking their effect. The company targets shared drivers of familial and

genomic and clinical dataset miningmachine learningoligonucleotide therapeutic design

ApoGlyx AB is a Swedish biopharmaceutical company founded in 2015 that develops first-in-class therapies based on aquaporin inhibitors. Its mission is to bring RG210179, a patented first-in-class Aquaporin-9 inhibitor for the treatment of acute pancreatitis, into a clinical development program. The company is located in Lund, within the Medicon Valley region.

preclinical developmentsmall molecule aquaporin-9 inhibitor development

Applied Cognition is a platform therapeutic company developing drugs to enhance brain glymphatic function and treat Alzheimer's disease. It has developed a first-in-human non-invasive glymphatic measurement platform with continuous, real-time assessment, validated against contrast-enhanced MRI, and has an active pipeline of lead compounds for indications such as Alzheimer's, Parkinson's, and Post-Traumatic Headaches.

AI integrationbiomarker assessmentdrug screeningglymphatic measurement platform

Apricity Health is a precision oncology company founded by physicians and scientists. It aims to bring world-class expert care to patients everywhere using digital health technologies and smart analytics, capturing longitudinal ePRO, EHR and genomic data from diverse patient populations to enhance care, learn from patient data, and develop precision therapeutics.

digital health technologiespatient data capturesmart analyticstherapeutic development

Arkana Therapeutics is an early-stage, Boulder-based drug discovery company developing oral small-molecule therapies for obesity and metabolic disease. Its platform draws on metabolic adaptations found in nature, such as those seen in animals that endure prolonged fasting and extreme weight fluctuations. The company has two programs: ARK-100, an oral small molecule acting on the brain to reduce calorie intake, and ARK-200, an early-development oral small molecule designed to increase energy expenditure.

in vitro and in vivo modelsmetabolomicssmall molecule development

Armida Labs, Inc. develops innovative, integrated drug discovery technologies aimed at changing the face of chemotherapy. Its science includes Targefrin, innovative anti-metastatic agents against pancreatic cancer and other solid tumors, and CovaLys, which targets tumor apoptosis via intelligent design of a Lysine covalent agent. The company also offers a technology platform for covalent drug discovery targeting His, Lys, or Tyr residues.

covalent drug discovery